Price$3.75-0.12 (-3.10%)
01:30 PM07:45 PM
News · 26 weeks62+50%
2025-12-142026-06-07
Mix3290d
- Other12(38%)
- Insider11(34%)
- SEC Filings6(19%)
- Earnings2(6%)
- Leadership1(3%)
Latest news
25 items- PRVerastem Oncology Announces U.S. FDA Fast Track Designation for VS-7375, an Oral and Potential Best-in-Class Investigational KRAS G12D (ON/OFF) Inhibitor for the Treatment of KRAS G12D-Mutated Locally Advanced or Metastatic Non-Small Cell Lung CancerPhase 1 TARGET-D 101 dose escalation, dose expansion, and combination clinical trial ongoing with early data updates expected in the first half of 2026 and more mature data expected in the second half of 2026 Phase 2 registration directed, open label TARGET-D 202 clinical trial initiated for 2L/3L advanced non-small cell lung cancer (NSCLC) FDA Fast Track Designation previously granted for VS-7375 for KRAS G12D-mutated advanced or metastatic pancreatic cancer Verastem Oncology (NASDAQ:VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced that the U.S. Food and Drug Administration (FDA) has granted Fas
- SECSEC Form S-8 filed by Verastem Inc.S-8 - Verastem, Inc. (0001526119) (Filer)
- INSIDERDirector Bailey Michael P was granted 108,000 shares (SEC Form 4)4 - Verastem, Inc. (0001526119) (Issuer)
- INSIDERSEC Form 3 filed by new insider Bailey Michael P3 - Verastem, Inc. (0001526119) (Issuer)
- SECSEC Form 144 filed by Verastem Inc.144 - Verastem, Inc. (0001526119) (Subject)
- PRVerastem Oncology to Present at Jefferies Healthcare ConferenceVerastem Oncology (NASDAQ:VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced that its management team is scheduled to participate in a fireside chat at the Jefferies Global Healthcare Conference on Wednesday, June 3, 2026, at 8:10 am ET in New York. A live webcast of the fireside chat can be accessed under "Events & Presentations" on the Company's website at www.verastem.com. A replay of the webcasts will be archived on the website for approximately 90 days following the presentation. About Verastem Oncology Verastem Oncology (NASDAQ:VSTM) is a biopharmaceutical company committed to developing and
- INSIDERDirector Tollefson Karin Anna was granted 36,000 shares, increasing direct ownership by 216% to 52,666 units (SEC Form 4)4 - Verastem, Inc. (0001526119) (Issuer)
- INSIDERDirector Stuglik Brian M was granted 36,000 shares, increasing direct ownership by 36% to 137,147 units (SEC Form 4)4 - Verastem, Inc. (0001526119) (Issuer)
- INSIDERDirector Rowinsky Eric K was granted 36,000 shares, increasing direct ownership by 216% to 52,666 units (SEC Form 4)4 - Verastem, Inc. (0001526119) (Issuer)
- INSIDERDirector Robertson Michelle was granted 36,000 shares, increasing direct ownership by 216% to 52,666 units (SEC Form 4)4 - Verastem, Inc. (0001526119) (Issuer)
- INSIDERDirector Kapur Anil was granted 36,000 shares, increasing direct ownership by 216% to 52,666 units (SEC Form 4)4 - Verastem, Inc. (0001526119) (Issuer)
- INSIDERDirector Bunn Paul A. was granted 36,000 shares, increasing direct ownership by 432% to 44,333 units (SEC Form 4)4 - Verastem, Inc. (0001526119) (Issuer)
- INSIDERDirector Johnson John was granted 36,000 shares, increasing direct ownership by 216% to 52,666 units (SEC Form 4)4 - Verastem, Inc. (0001526119) (Issuer)
- SECVerastem Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders8-K - Verastem, Inc. (0001526119) (Filer)
- PRVerastem Oncology Appoints Michael P. Bailey to its Board of DirectorsVerastem Oncology (NASDAQ:VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced the appointment of Michael P. Bailey to its Board of Directors. The Company also announced that Robert Gagnon stepped down from the Board following the end of his term on May 21, 2026. "We are excited to have Michael join our Board as he brings more than three decades of experience leading global pharmaceutical and biotechnology companies, with a proven track record of taking oncology medicines from clinical development through successful commercialization, including landmark therapies like ERBITUX®," said Daniel Paterson, pre
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Verastem Inc.SCHEDULE 13G/A - Verastem, Inc. (0001526119) (Subject)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Verastem Inc.SCHEDULE 13G/A - Verastem, Inc. (0001526119) (Subject)
- PRVerastem Oncology to Present at Upcoming Investor ConferencesVerastem Oncology (NASDAQ:VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced that its management team is scheduled to participate and present at the following investor conferences in New York City: HCW 4th Annual BioConnect Investor Conference: Tuesday, May 19, 2026, 4:00-4:30 pm ET RBC Global Healthcare Conference: Wednesday, May 20, 2026, 9:30-9:55 am ET A live webcast of the fireside chat can be accessed under "Events & Presentations" on the Company's website at www.verastem.com. A replay of the webcasts will be archived on the website for approximately 90 days following the presentation. A
- PROn World Ovarian Cancer Day, LGSOC Resource Guide Launches to Support People Living with Low-Grade Serous Ovarian CancerAvailable at LGSOCAwarenessDay.Org, the LGSOC Resource Guide brings together resources from patient advocacy groups, covering topics from diagnosis to survivorship Today, STAAR Low-Grade Serous Ovarian Cancer Foundation, Not These Ovaries, and Verastem Oncology announced the launch of the LGSOC Resource Guide, a unique resource designed to support patients living with low-grade serous ovarian cancer (LGSOC), a rare and distinct form of ovarian cancer, along with their caregivers and advocates. Available at www.LGSOCAwarenessDay.org, the guide launches in conjunction with World Ovarian Cancer Day, a global effort to raise awareness of all types of ovarian cancer. This press release featur
- SECVerastem Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - Verastem, Inc. (0001526119) (Filer)
- SECSEC Form 10-Q filed by Verastem Inc.10-Q - Verastem, Inc. (0001526119) (Filer)
- PRVerastem Oncology Reports First Quarter 2026 Financial Results and Highlights Recent Business UpdatesAVMAPKI® FAKZYNJA® CO-PACK net product revenue of $18.7 million Appointed Daniel Lyons as Chief Commercial Officer to lead next phase of commercial growth Initiated Phase 2 registration-directed trials "VS-7375 TARGET-D Clinical Program" in 2L PDAC, 2L/3L NSCLC and 2L+ CRC VS-7375 TARGET-D 101 early data update expected in the first half of 2026; mature data update expected in the second half of 2026 Ended Q1 2026 with $181.7 million in cash, cash equivalents and investments; expected cash runway into first half of 2027 Company to host a conference call and webcast today at 4:30 p.m. ET Verastem Oncology (NASDAQ:VSTM), a biopharmaceutical company committed to advancing new medic
- INSIDERPresident and CEO Paterson Dan sold $4,691 worth of shares (806 units at $5.82), decreasing direct ownership by 0.13% to 612,113 units (SEC Form 4)4 - Verastem, Inc. (0001526119) (Issuer)
- PRVerastem Oncology Launches HCP and Patient Reimagine Campaign to Increase Awareness of AVMAPKI® FAKZYNJA® CO-PACK for KRAS-Mutated Recurrent Low-Grade Serous Ovarian CancerLow-grade serous ovarian cancer (LGSOC) is a rare ovarian cancer with a high rate of recurrence affecting more than 80% of patients Integrated healthcare professional (HCP) and patient campaign features new websites and expanded digital resources about the first and only treatment specifically FDA-approved for KRAS-mutated recurrent LGSOC who have received prior systemic therapy Verastem Oncology (NASDAQ:VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced the launch of its Reimagine Recurrent Low-Grade Serous Ovarian Cancer (LGSOC) campaign for AVMAPKI® FAKZYNJA® CO-PACK (avutometinib capsules; defact
- PRVerastem Oncology to Report First Quarter 2026 Financial Results on May 7, 2026Verastem Oncology (NASDAQ:VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced that the Company will host a conference call and webcast to discuss its first quarter 2026 financial results and business updates on Thursday, May 7, 2026, at 4:30 pm ET. A live audio webcast of the call, along with accompanying slides, will be available under "Events & Presentations" in the Investor section of the Company's website, https://investor.verastem.com/events. A replay of the webcast will be archived and available following the event. About Verastem Oncology Verastem Oncology (NASDAQ:VSTM) is a biopharmaceutical
VSTM FAQ
7 questionsWhat does Verastem Inc. do?
Verastem, Inc., a development-stage biopharmaceutical company, focusing on developing and commercializing medicines to enhance the life of cancer patients. Its product in development include VS-6766, a dual rapidly accelerated fibrosarcoma (RAF)/mitogen-activated protein kinase (MEK) inhibitor that blocks MEK kinase activity and the ability of RAF to phosphorylate MEK. The company also engages in developing RAMP 201, an adaptive two-part multicenter open label trial to evaluate the efficacy and safety of VS-6766 and in combination with defactinib, an oral small molecule inhibitor of focal...Where does VSTM stock trade?
Verastem Inc. (VSTM) is listed on NASDAQ.What sector and industry is VSTM in?
Verastem Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Verastem Inc. go public?
Verastem Inc. (VSTM) completed its IPO in 2012.What are analysts saying about VSTM?
Verastem Inc. has had 8 recent analyst actions on file. The most recent action was from BTIG Research: Buy with a $1900.00 price target on 2026-03-12. Recent price targets range from $1000.00 to $2700.00.What companies are similar to VSTM?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), AZN (AstraZeneca PLC), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.). Compare VSTM side-by-side with any of them on Quantisnow.How can I track VSTM on Quantisnow?
Quantisnow aggregates Verastem Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow VSTM to receive live email and push alerts on every new disclosure.